We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Intravascular Cooling in the Treatment of Stroke 2/3 Trial (ICTuS2/3)

This study has been terminated.
(The ICTuS 2 portion of the trial has been halted and data will be analyzed.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01123161
First Posted: May 14, 2010
Last Update Posted: April 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS)
The University of Texas Health Science Center, Houston
Information provided by (Responsible Party):
Patrick Lyden, Cedars-Sinai Medical Center
April 27, 2010
May 14, 2010
September 29, 2016
April 5, 2017
April 5, 2017
June 2010
January 2015   (Final data collection date for primary outcome measure)
  • The Primary Outcome is the Proportion of Patients Achieving a Favorable Outcome Defined as Modified Rankin Scale Score of 0 or 1, Assessed 90 Days After Treatment. [ Time Frame: 90 days ]
    Modified Rankin describes disability: 0 is free of any disability or symptoms, 6 is death, and higher grades between 0 and 6 reflect progressively greater disability
  • Incidence of Any Intracranial Hemorrhage (ICH) Within 48 Hours of Stroke Onset [ Time Frame: 48 hours ]
    Incidence (number) of any intracranial hemorrhage (ICH) (whether or not symptomatic) within 48 hours of stroke onset will be presented by treatment group and overall.
  • Incidence of Any Symptomatic Intracranial Hemorrhage (sICH) Within 48 Hours of Stroke Onset [ Time Frame: 48 hours ]
    Incidence (number) of Symptomatic ICH (sICH) within 48 hours of stroke onset will be presented by treatment group and overall. Patients with neuroworsening (4 or more point increase in NIHSS , or a decline in the NIHSS consciousness item 1A score of more than 1 point, or a motor deterioration lasting more than 8 hours, all not due to iatrogenic cause) and hemorrhage seen on brain images in whom the investigator attributes the clinical change to the hemorrhage.
  • Incidence of Pneumonia [ Time Frame: 7 days or discharge whichever comes first ]
    Number subjects diagnosed with pneumonia according to CDC criteria will be presented by treatment group and overall, regardless of seriousness
  • 90 Day Mortality [ Time Frame: 90 days ]
    Mortality prior to the 90-day evaluation.
The Primary Outcome is the Proportion of Patients Achieving a Favorable Outcome Defined as Modified Rankin Scale Score of 0 or 1, Assessed 90 Days After Treatment. [ Time Frame: 90 days ]
Complete list of historical versions of study NCT01123161 on ClinicalTrials.gov Archive Site
  • The Barthel Index Measure of Activities of Daily Living; [ Time Frame: 90 days ]
    The Barthel index measures independence in activities of daily living from 0 (worst) to 100 (best) in 5 point increments. Higher scores between 0 and 100 reflect progressively greater levels of independence. Scores were dichotomized at 90 so that a score of 95 or 100 was considered a successful treatment.
  • NIHSS Scores at 90 Days [ Time Frame: 90 days ]
    The National Institutes of Health Stroke Scale (NIHSS) is used to quantify neurological deficit. The scale ranges from 0 (best) to 42 points (worst). Between scores of 0 to 42, higher values reflect progressively greater deficit.
  • The NIH Stroke Scale measure of neurologic deficit; the Barthel Index measure of activities of daily living; the Modified Rankin Scale measure of the degree of disability or dependence in daily activities [ Time Frame: 90 days ]
  • 90 day mortality [ Time Frame: 90 days ]
Not Provided
Not Provided
 
The Intravascular Cooling in the Treatment of Stroke 2/3 Trial
Phase 2/3 Study of Intravenous Thrombolysis and Hypothermia for Acute Treatment of Ischemic Stroke
The purpose of this trial is to determine whether the combination of thrombolysis and hypothermia is superior to thrombolysis alone for the treatment of acute ischemic stroke.

A stroke is usually caused by a blockage in one of the arteries that carries blood to the brain. Research has shown that tissue plasminogen activator (tPA)—a naturally occurring protein that opens blocked arteries by dissolving blood clots — activates the body's ability to dissolve recently formed blood clots and reduces or prevents the brain damage caused by a stroke.

The Food and Drug Administration (FDA) has approved the use of tPA for people having a stroke when taken within 3 hours of stroke onset.

Researchers believe that a lower body temperature (hypothermia) may be beneficial while a stroke is happening because hypothermia may prevent further brain injury, or may make the stroke less damaging.

Patients will receive a standard stroke evaluation, which includes blood tests, a computed tomography (CT) scan, complete physical and neurological examinations, and an electrocardiogram (EKG) to determine eligibility for the study.

There are two study groups - tPA alone or tPA with cooling (hypothermia). Participants will be randomly assigned to one of the two study groups. Length of participation (including observation after the patient leaves the hospital) is 90 days.

This study is part of the Specialized Program of Translational Research in Acute Stroke (SPOTRIAS), which allows researchers to enhance and initiate translational research that ultimately will benefit stroke patients by treating more patients in less than 2 hours, and finding ways to treat additional patients later.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Factorial Assignment
Intervention Model Description:
Randomized to normothermia or hypothermia
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Stroke, Acute
  • Device: hypothermia and anti-shivering treatment
    Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
    Other Name: cooling
  • Drug: Group1: IV t-PA and normothermia
    Group 1 will t-PA as standard of care and normothermia
  • Active Comparator: Group1: IV t-PA and normothermia
    IV tpa and normothermia
    Intervention: Drug: Group1: IV t-PA and normothermia
  • Active Comparator: Group 2 : IV t-PA and hypothermia and anti-shivering treatment
    IV tpa and hypothermia and anti-shivering treatment
    Intervention: Device: hypothermia and anti-shivering treatment

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
120
May 2015
January 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age 22 to 82 years old inclusive
  2. Patient receiving IV rt-PA using standard guidelines
  3. NIHSS score ≥ 7 and ≤ 20 (right hemisphere) or ≥ 7 and ≤ 24 (left hemisphere) at the time of randomization
  4. Pre-stroke mRS 0-1
  5. Able to begin endovascular phase of hypothermia within 2 hours of tPA completion
  6. Written Informed Consent, signed and dated by the patient (or patient's authorized representative)

Exclusion Criteria:

  1. Etiology other than ischemic stroke
  2. Item 1a on NIHSS > 1 at the time of randomization
  3. Clinical symptoms consistent with brainstem or cerebellar stroke
  4. Classic lacunar syndrome with imaging confirmation of small deep ischemia, but randomization will not be delayed for neuroimaging other than initial scan to exclude hemorrhage
  5. Known contraindications to hypothermia, such as known hematologic dyscrasias that affect thrombosis (cryoglobulinemia, Sickle cell disease, serum cold agglutinins), or vasospastic disorders such as Raynaud's or thromboangiitis obliterans
  6. Known co-morbid conditions that are likely to complicate therapy in the opinion of the investigator, e.g., i. Heart failure (NYHA class III and IV)* ii. Uncompensated arrhythmia iii. Severe Liver disease iv. History of pelvic or abdominal mass likely to compress inferior vena cava v. IVC filters vi. HIV positive vii. Clinically active hypo or hyperthyroidism viii. Renal insufficiency likely to impair meperidine clearance ix. Chronic ethanol abuse x. History of HIT (heparin induced thrombocytopenia)
  7. Pregnancy (All women of child-bearing potential must have a negative pregnancy test, urine or blood, prior to therapy.)
  8. Medical conditions likely to interfere with patient assessment.
  9. Known allergy to meperidine or buspirone
  10. Currently taking or used within previous 14 days MAO-I class of medication.
  11. Life expectancy < 6 months
  12. Not likely to be available for long-term follow-up
  13. Use, or planned use, of intra-arterial thrombolysis, mechanical clot removal, or other experimental or approved acute therapy for this stroke event
  14. Chest radiograph or clinical presentation suggestive of pneumonia or clinically significant pulmonary edema at baseline.
  15. Temperature upon admission greater than or equal to 38°C
Sexes Eligible for Study: All
22 Years to 82 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Switzerland,   United States
 
 
NCT01123161
ICTuS2/3
P50NS044148 ( U.S. NIH Grant/Contract )
P50NS044227 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Plan to Share IPD: Undecided
Patrick Lyden, Cedars-Sinai Medical Center
University of California, San Diego
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • The University of Texas Health Science Center, Houston
Principal Investigator: Patrick D. Lyden, MD Cedars-Sinai Medical Center
Study Director: Thomas M. Hemmen, MD, PhD University of California, San Diego
Study Director: James C. Grotta, MD The University of Texas Health Science Center, Houston
University of California, San Diego
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP